Multiplex immunoassay for simultaneous diagnostic of autoimmune diabetes mellitus and celiac disease
DOI:
https://doi.org/10.47196/diab.v54i1.174Keywords:
autoimmune diabetes mellitus, celiac disease, autoantibodies, multiplex immunoassayAbstract
Introduction: autoimmune diabetes mellitus (ADM) and celiac disease (CD) are chronic, polygenic and multifactorial diseases associated with immune system dysfunction. As it is frequent that a patient presents both pathologies, the simultaneous detection of autoimmunity markers of ADM and CD would be a rational strategy to improve the diagnosis.
Objectives: to develop an immunoassay based on Flow Cytometry (FloCMIA multiplex) for the simultaneous and discriminative detection of markers for ADM (GADA and IA-2A) and CD (tTgA).
Materials and methods: thirty five serum samples of control individuals and 21 type 1 DM patients were assayed. A “double bridge” model was used for the assay, incubating the serum samples with a mixture of microspheres containing different amount of internal fluorescence, each one adsorbed with an autoantigen: TrxGAD, TrxIA-2 or H6tTg, and a mixture of the same biotinilated autoantigens. The immunocomplexes were detected using streptavidin-phycoerytrin and then acquired in a flow cytometer.
Conclusions: FloCMIA multiplex allowed detecting and discriminating GADA, IA-2A and/or tTgA, -in a single assay- in serum samples of ADM and/or CD. The novel developed immunoassay simplifies the screening of the large scale population.
References
I. Palmer JP, Hirsch IB. What’s in a name: Latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes. Diabetes Care 2003; 26:536-538. doi:10.2337/diacare.26.2.536.
II. Zimmet PZ, Shaten BJ, Kuller LH, et al. Antibodies to glutamic acid decarboxylase and diabetes mellitus in the multiple risk factor intervention trial. American Journal of Epidemiology 1994; 140:683-690. doi:10.1093/oxfordjournals.aje.a117316.
III. Lohi S, Mustalahti K, Kaukinen K, et al. Increasing prevalence of coeliac disease over time. Alimentary Pharmacology & Therapeutics 2007; 26:1217-1225. doi:10.1111/j.1365-2036.2007.03502.x.
IV. Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. PubMed - NCBI. Arch Intern Med 2003; 163:286-292. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/12578508.
V. Husby S, Koletzko S, Korponay-Szabó IR, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition Guidelines for the Diagnosis of Coeliac Disease. Journal of Pediatric Gastroenterology and Nutrition 2012; 54:136-160. doi:10.1097/MPG.0b013e31821a23d0.
VI. Bao F, Yu L, Babu S, et al. One third of HLA DQ2 homozygous patients with type 1 diabetes express celiac disease-associated transglutaminase autoantibodies. Journal of Autoimmunity 1999; 13:143-8. doi:10.1006/jaut.1999.0303.
VII. Chiang JL, Kirkman MS, Laffel LMB, et al. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 2014; 37:2034-2054. doi:10.2337/dc14-1140.
VIII. Diabetes mellitus. Report of a WHO Study Group. World Health Organization Technical Report Series 1985; 727:1-113. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/3934850.
IX. Grubin CE, Daniels T, Toivola B, et al. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 1994; 37:344-50. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/8063033.
X. Gianani R, Rabin DU, Verge CF, et al. ICA512 Autoantibody radioassay. Diabetes 1995; 44:1340-1344. doi:10.2337/diab.44.11.1340.
XI. Papouchado ML, Valdez SN, Ghiringhelli D, et al. Expression of properly folded human glutamate decarboxylase 65 as a fusion protein in Escherichia coli. European Journal of Biochemistry 1997; 246:350-9. Disponible en: doi:10.1111/j.1432-1033.1997.00350.x.
XII. Guerra LL, Faccinetti NI, Trabucchi A, et al. Novel prokaryotic expression of thioredoxin-fused insulinoma associated protein tyrosine phosphatase 2 (IA-2), its characterization and immunodiagnostic application. BMC Biotechnology 2016; 16:84. Disponible en: doi:10.1186/s12896-016-0309-2.
XIII. Hoffman RD, Lane MD. Iodophenylarsine oxide and arsenical affinity chromatography: new probes for dithiol proteins. Application to tubulins and to components of the insulin receptor-glucose transporter signal transduction pathway. The Journal of Biological Chemistry 1992; 267:14005-11.
XIV. Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychological Bulletin 1968; 70:213-20. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19673146.
XV. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33:159-74. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/843571.
XVI. Koch GG, Landis JR, Freeman JL, et al. A general methodology for the analysis of experiments with repeated measurement of categorical data. Biometrics 1977; 33:133-58. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/843570.
XVII. Törn C, Mueller PW, Schlosser M, et al. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008; 51:846-52. doi:10.1007/s00125-008-0967-2.
XVIII. Villalba A, Valdez SN, Iacono RF, et al. Development of 2 alternative enzyme-linked immunosorbent assays for routine screening of glutamic acid decarboxylase autoantibodies. Clinica Chimica Acta; International Journal of Clinical Chemistry 2007; 376:82-7. doi:10.1016/j.cca.2006.07.017.
XIX. Guerra LL, Faccinetti NI, Bombicino SS, et al. Novedoso inmunoensayo multiplex por citometría de flujo para la detección simultánea y discriminativa de GADA e IA2A en pacientes con Diabetes Mellitus. Revista de la Asociación Bioquímica Argentina, Bioquímica y Patología Clínica 2018; 82:14-26. Disponible en: https://www.aba-online.org.ar/ejemplares-revista-bypc-2018/revista-aba-vol-82-n-1-ene-abril-2018.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
